A

Agile Therapeutics Inc
F:0AL

Watchlist Manager
Agile Therapeutics Inc
F:0AL
Watchlist
Price: 1.11 EUR -1.77% Market Closed
Market Cap: 9.3m EUR
Section:
Wall Street Price Targets
Wall Street Price Targets
Revenue Forecast
Operating Income Forecast
Net Income Forecast
See Also
Price Target
Average
-4%
Revenue
Forecast
+7%
Operating Income
Forecast
+14%
Net Income
Forecast
+13%

Wall Street
Price Targets

0AL Price Targets Summary
Agile Therapeutics Inc

There are no price targets for 0AL.
0AL Lowest Forecast
Wall Street Target
Not Available
0AL Average Forecast
Wall Street Target
Not Available
0AL Highest Forecast
Wall Street Target
Not Available
Lowest
Price Target
Not Available
Average
Price Target
Not Available
Highest
Price Target
Not Available
Agile Therapeutics Inc Competitors:
Price Targets
SUPN
Supernus Pharmaceuticals Inc
28% Upside
NWRN
Newron Pharmaceuticals SpA
151% Upside
688513
Chengdu Easton Biopharmaceuticals Co Ltd
5% Upside
600195
China Animal Husbandry Industry Co Ltd
10% Upside
SUPN
Supernus Pharmaceuticals Inc
28% Upside
NWRN
Newron Pharmaceuticals SpA
151% Upside
688513
Chengdu Easton Biopharmaceuticals Co Ltd
5% Upside
600195
China Animal Husbandry Industry Co Ltd
10% Upside
OCUL
Ocular Therapeutix Inc
88% Upside

Revenue
Forecast

Revenue Estimate
Agile Therapeutics Inc

The compound annual growth rate of Agile Therapeutics Inc's revenue for the next 1 year is 81%.

N/A
Past Growth
81%
Estimated Growth
N/A
Estimates Accuracy
N/A
Average
What are analyst estimates?

Operating Income
Forecast

Operating Income Estimate
Agile Therapeutics Inc

Operating Income forecast
is not available for
Agile Therapeutics Inc

Net Income
Forecast

Net Income Estimate
Agile Therapeutics Inc

N/A
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average
What are analyst estimates?

See Also

Summary
0AL intrinsic value, competitors valuation, and company profile.
DCF Valuation
0AL stock valuation using Discount Cash Flow valuation method.
Relative Valuation
0AL stock valuation using valuation multiples.
Wall Street Estimates
0AL price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
0AL stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is 0AL's stock price target?
Not Available

0AL doesn't have any price targets made by Wall Street professionals.

What is Agile Therapeutics Inc's Revenue forecast?
Projected CAGR
81%

The compound annual growth rate of Agile Therapeutics Inc's revenue for the next 1 year is 81%.

Back to Top
ALPHA SPREAD
Follow us
Join more than 264,200+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.